Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...